Forte Biosciences (FBRX) Non-Current Debt (2016 - 2019)

Forte Biosciences (FBRX) has 4 years of Non-Current Debt data on file, last reported at $22.1 million in Q2 2019.

• On a quarterly basis, Non-Current Debt fell 14.8% year-over-year to $22.1 million in Q2 2019; TTM through Jun 2019 was $22.1 million, a 14.8% decrease from a year earlier, with the FY2018 full-year figure at $26.2 million, up 622.79% from the prior year.
• Non-Current Debt for Q2 2019 stood at $22.1 million, down from $24.1 million in the prior quarter.
• Over the last five years, Non-Current Debt for FBRX reached as high as $26.2 million in Q4 2018 and fell as low as $2.0 million in Q1 2018.
• Historically, Non-Current Debt has averaged $14.6 million across 4 years, with a median of $10.2 million in 2016.
• Across the five-year window, Non-Current Debt plunged 77.02% in 2018 and soared 1124.09% in 2019, its largest moves.
• Year by year, Non-Current Debt stood at $10.2 million in 2016, then sank by 64.6% to $3.6 million in 2017, then soared by 622.79% to $26.2 million in 2018, then decreased by 15.73% to $22.1 million in 2019.
• Per Business Quant data, the three most recent Non-Current Debt figures were $22.1 million in Q2 2019, $24.1 million in Q1 2019, and $26.2 million in Q4 2018.